Stifel downgrades Baxter as it sees longer path to recovery under new CEO

Published 04/08/2025, 14:40
© Reuters.

Investing.com -- Stifel downgraded Baxter International (NYSE:BAX) to Hold from Buy and slashed its price target to $25 from $36, citing a weaker-than-expected second quarter and a longer timeline for operational turnaround under incoming CEO Andrew Hider.

The firm said multiple issues weighed on Baxter’s Q2 results and full-year guidance, particularly soft U.S. Infusion Therapies & Technologies (ITT (NYSE:ITT)) revenue, which missed expectations due to lower hospital admissions and IV solution conservation.

Sales of $2.81 billion slightly missed consensus, while EPS of $0.59 fell short despite a lower tax rate. Margins also disappointed, with gross margin at 40.7% and operating margin at 15.1%, both below expectations.

Stifel expressed concern that many of Baxter’s challenges, including paused shipments of the NOVUM large volume pump are unlikely to be resolved quickly.

“We find ourselves believing that BAX is in an extended transition period,” the note said, adding that margin expansion and mid-single-digit sales growth targets may be harder to achieve near-term.

The downgrade comes ahead of Hider’s start as CEO in early September. While Stifel acknowledged his strong operational track record, it noted that real strategic change and execution improvement could take at least a year.

Baxter is still working through the impact of past missteps, including integration challenges from the Hill-Rom (NYSE:HRC) acquisition and recent business separations.

Looking ahead, pricing benefits that helped growth in 2023 and 2024 are expected to fade in 2026, adding another headwind. Stifel remains cautious until there is more clarity on Hider’s strategy and signs of sustained execution.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.